Managing Constipation in Patients Taking GLP-1 Receptor Agonists
Understanding the Mechanism
- GLP-1 receptors on the myenteric plexus activate nitrergic pathways that inhibit vagal activity on the gut, leading to reduced phasic gastric contractions and delayed gastric emptying, affecting the entire gastrointestinal tract and contributing to constipation as a common adverse effect 2
- The effect of GLP-1 receptor agonists on constipation is dose-dependent and occurs more frequently with short-acting formulations than long-acting preparations 1
Management Strategy
Initial Prevention Approach
- Starting with slow dose titration to minimize gastrointestinal side effects is recommended, beginning at the lowest available dose and increasing gradually over weeks to months to increase gastrointestinal tolerability 1, 3
Standard Constipation Management
- The American College of Gastroenterology recommends using conventional constipation therapies, such as osmotic laxatives, stimulant laxatives, and stool softeners, while continuing GLP-1 therapy 3
- Adequate hydration, with at least 8 glasses of water daily, is also recommended 3
When to Consider Medication Adjustment
- Avoiding GLP-1 receptor agonists entirely in patients with pre-existing gastroparesis is recommended 1
- Evaluating for dose reduction if glycemic control and weight loss goals permit, and assessing for other contributing medications or conditions, is recommended if constipation becomes severe or refractory despite conservative measures 1, 3
Common Pitfalls to Avoid
- Not discontinuing GLP-1 therapy prematurely for mild constipation, as most gastrointestinal adverse events are manageable with supportive care and often improve with continued use due to tachyphylaxis, is recommended by the American Gastroenterological Association 1, 2